Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ELI LILLY AND COMPANY

(LLY)
  Report
Delayed Nyse  -  04:03 2022-12-07 pm EST
371.97 USD   +0.93%
12/07Eli Lilly's Phase 3 Trial of Jardiance Meets Primary Goal
MT
12/07Guggenheim Adjusts Eli Lilly's Price Target to $401 From $399, Keeps Buy Rating
MT
12/07Eli Lilly Meets Primary Endpoint for Diabetes Drug's Use in Children, Adolescents
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nyse
12/01/2022 12/02/2022 12/05/2022 12/06/2022 12/07/2022 Date
370.33(c) 374.76(c) 369.29(c) 368.54(c) 371.97(c) Last
2 516 098 1 925 568 2 296 532 1 970 992 1 629 084 Volume
-0.20% +1.20% -1.46% -0.20% +0.93% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 28 688 M - -
Net income 2022 6 187 M - -
Net Debt 2022 10 498 M - -
P/E ratio 2022 55,9x
Yield 2022 1,00%
Sales 2023 30 102 M - -
Net income 2023 7 478 M - -
Net Debt 2023 7 301 M - -
P/E ratio 2023 43,6x
Yield 2023 1,11%
Capitalization 353 B 353 B -
EV / Sales 2022 12,7x
EV / Sales 2023 12,0x
Nbr of Employees 35 000
Free-Float 99,8%
More Financials
Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (46.6%): products for treating osteoporosis, diabetes, and growth problems; - oncology (20.3%); - immunology diseases (11.8%); - neurology (6.7%): primarily drugs used in treating depression and schizophrenia; - other (14.6%). Net sales are distributed geographically... 
Sector
Pharmaceuticals
Calendar
12/10 | 03:00pmPresentation
More about the company
Ratings of Eli Lilly and Company
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ELI LILLY AND COMPANY
12/07Eli Lilly's Phase 3 Trial of Jardiance Meets Primary Goal
MT
12/07Guggenheim Adjusts Eli Lilly's Price Target to $401 From $399, Keeps Buy Rating
MT
12/07Eli Lilly Meets Primary Endpoint for Diabetes Drug's Use in Children, Adolescents
MT
12/07Phase III trial demonstrated Jardiance« is the first SGLT2 inhibitor to show statistica..
PR
12/07Boehringer Ingelheim and Eli Lilly and Company Announces Phase III Trial Demonstrates J..
CI
12/07Boehringer Ingelheim and Eli Lilly and Company Announce Phase III Trial Demonstrated Ja..
CI
12/06Eli Lilly Says Follow-up Data from Phase 3 Verzenio Trial Show Continued Increase in Su..
MT
12/06Eli Lilly and Company Announces Updated Data from the Verzenio (Abemaciclib) Phase 3 Mo..
CI
12/06Major Pharma Companies to Remain Defensive Through at least H1 2023 Amid M&As, New Prod..
MT
12/06Credit Suisse Raises Eli Lilly's Price Target to $400 From $395, Keeps Outperform Ratin..
MT
12/06Morgan Stanley Boosts Price Target on Eli Lilly to $446 From $436, Maintains Overweight..
MT
12/06Chronic Lower Back Pain Pipeline Offers Novel Treatment Options | 10+ Companies & 10+ D..
AQ
12/05Cowen Boosts Price Target on Eli Lilly to $430 From $390, Maintains Outperform Rating
MT
12/05SonoThera announced that it has received $60.75 million in funding from a group of inve..
CI
12/03Amgen says experimental obesity drug has promising durability
RE
More news
News in other languages on ELI LILLY AND COMPANY
12/07L'essai de phase 3 de Jardiance d'Eli Lilly atteint son objectif principal
12/07Eli Lilly : essai prometteur dans le diabète des adolescents
12/07Boehringer Ingelheim et Eli Lilly and Company annoncent que l'étude de phase III démont..
12/07Boehringer Ingelheim et Eli Lilly and Company annoncent que l'étude de phase III a démo..
12/07Eli Lilly : annonce de nouvelles données pour Verzenio
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Stock Trading Strategies
ELI LILLY AND COMPANY - 03/29
The trend should regain control
BUY
More Stock Trading Analysis
ETFs positioned on ELI LILLY AND COMPANYETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Nomura NEXT FUNDS International Equity MSCI...6.49%-0.46%-World
Invesco Dynamic Pharmaceuticals ETF - USD6.14%1.09%United_States
VanEck Vectors Pharmaceutical ETF - USD5.94%0.78%United_States
The Health Care Select Sector SPDR Fund - USD5.64%-0.36%United_States
SPDR S&P U.S. Health Care Select Sector - USD5.64%1.64%United_States
More ETFs positioned on ELI LILLY AND COMPANY
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 371,97 $
Average target price 373,82 $
Spread / Average Target 0,50%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Alonzo Weems Senior VP, Chief Ethics & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY33.42%353 438
JOHNSON & JOHNSON2.94%463 208
ABBVIE INC.22.16%292 407
NOVO NORDISK A/S20.94%283 266
PFIZER, INC.-15.82%282 013
MERCK & CO., INC.43.65%279 122